Skip to content


Breakthrough small molecule medicines for chronic disease with unprecedented pathway precision and predictable discovery

About Montai

Montai is a different kind of drug company, purpose-built to make big leaps forward in the predictable discovery of great drugs for chronic diseases.

Montai is pioneering at the intersection of technology, validated biology, and a space of diverse, untapped chemistry that is rich with new potential solutions to disease – Anthromolecules™. Tested and refined through eons of human co-evolution through chronic consumption, Anthromolecules are capable of targeting complex biology in new ways and offer a powerful starting point for small molecule drugs.

Using leading edge AI and end to end automation, Montai finds and prioritizes promising drug leads in this vast and untapped chemical space. The result: small molecule drug discovery that is more predictable and productive than ever before.

A graphic displaying a the outline of a human body, zooming in on a section of Anthromolecules — a privileged class of molecules with a history of safe, human consumption.
What if AI could unlock the predictable discovery of transformative small molecule drugs for chronic disease?

Our Mission

Our understanding of human biology has grown exponentially, offering new insights into disease and ways to intervene. Yet many of today’s innovative therapies remain out of reach or insufficient for most patients. What’s more, finding new oral medicines has historically been largely a trial-and-error endeavor. Montai aims to change this.

  • 2 Billion
    People living with
    chronic diseases
  • >50%
    Most severe patients
    are untreated
  • <10%
    Proportion of innovative medicines taken that are small molecules
  • 7%
    Likelihood of approval for novel small molecules

Our Approach

Predictable discovery and pathway precision. In a pill.

Predictable and Highly Productive Drug Discovery

Drug discovery began as a serendipitous, trial-and-error effort. Montai is pioneering a new era of predictable discovery for small molecule medicines that would not have been possible even a few years ago. Fueled by the exponential growth in biochemical data over the last decade and far more powerful computational tools, we are decoding the complex language of chemistry computationally, generating deep understanding of the structure-function relationships in any molecule to efficiently predict its potential to become a drug.

When we apply these powerful tools to aggregate and then survey the landscape of Anthromolecule chemistry, we can predictably and hyper-efficiently find and validate the best possible keys to unlock any biology pathway door.

Diverse, Untapped Chemistry at Industrial Scale

Montai is aggregating and curating the world's largest, fully-annotated library of Anthromolecule chemistry - bioactive molecules humans have chronically consumed in foods, supplements, and herbal medicines. The 125,000+ bioactive Anthromolecules in our library today offer 2-3 times greater chemical diversity and scaffolds than standard synthetic chemistry libraries.

Anthromolecule chemistry is a proven source of chronically-dosed, FDA-approved drugs for many diseases, but has yet to be systematically and predictably mined for drug development.

Precision Matched to Biology

Anthromolecules have co-evolved in humans over millennia, interacting with our own biology to maintain health. More than 85% of Anthromolecules are structurally unique versus synthetic libraries most drug development focuses on today, presenting a far greater variety of building blocks for engaging disease pathways that have eluded traditional medicinal chemistry approaches. Montai’s AI tools unlock precision connections between this diverse chemistry and the known drivers of complex disease biology presenting entirely new ways to treat diseases with a pill.

A graphic representation of Anthromolecules, highlighting the ratio of known versus FDA-approved.
Anthromolecules are a diverse, untapped chemical source. There are currently more than 100,000 known Anthromolecules, and more than 40,000 already found in FDA-approved drugs safe for long term use.

The CONECTA™ Platform

The CONECTA™ Platform is a new drug operating system enabling the predictable discovery of transformative small molecule drugs from diverse chemistry.

Unlike other small molecule AI approaches that focus on physical binding to a specific target, Montai's CONECTA platform starts with validated pathways and nominates chemistry that will modulate the pathway to drive the desired therapeutic effect.

These bioactive nominations are then filtered for drug-like properties and ranked with CONECTA's proprietary ML tools, allowing scientists to select and focus optimization efforts on the most promising leads.

CONECTA supercharges drug discovery and development with incredible efficiency, insights, and optionality by enabling far more and earlier integrative decision making across multiple differentiated candidates to reduce risk.



Multidimensional, pharmacological characterization and scoring of every known Anthromolecule across 45+ properties essential to drug development.

Bioactivity Atlas

Hyper-efficient chemical machine learning-powered mapping and ranking of bioactive connections between every Anthromolecule and the pathways known to drive specific diseases.

Pathway Solutions

Molecules that potently modulate known pathways underlying chronic disease with the potential to become effective oral medicines that offer novel solutions.

The CONECTA™ pipeline

Montai is rapidly advancing a pipeline of small molecule programs against validated biological pathways that have been undruggable using medicinal chemistry — until now.
  • 125K+
    Over 125,000 AnthroGraphs
  • 13 / 5
    13 Pathway Maps in 5 major disease areas
  • 1000x
    1000x efficiency in finding high potential keys for complex targets

Our initial focus is on inflammatory and autoimmune diseases given the enormous unmet patient needs for efficacious, accessible therapies that are safe for long-term use and earlier intervention.

Inflammation-related pathways also offer important biological network links to other chronic diseases such metabolism, neurology and oncology. Our CONECTA platform has generated multiple promising candidates that have the potential to replace biologics or effectively engage targets that have historically been intractable, like transcription factors.

We envision a world where, instead of regular and costly infusions, a convenient and safe pill for long-term use effectively treats a chronic disease, where solutions exist for diseases that today have none.

We are climbing mountains with AI, determined to improve health outcomes for as many people as possible to reduce the growing and unsustainable burden of chronic disease.
Meet Our Team

Featured News

  • Montai Therapeutics Appoints Renowned Chemical Innovator Larry Hamann to Company's Board of Directors, Convenes Multidisciplinary Scientific Advisory Board to Inform Strategic Momentum

    May 29, 2024
    Read on Business Wire
  • How 3 Mass. companies are using AI to design drugs

    Mar 19, 2024
    Read on WBUR
  • Breaking Boundaries in Chemical Combinatorics Machine Learning: Unveiling the ComboPath Model at NeurIPS 2023

    Dec 13, 2023
    Read on LinkedIn
  • Montai Health Appoints Christian Antoni, M.D., Ph.D., as Company's First Chief Medical Officer

    Press Release
    Oct 24, 2023
    Read on GlobeNewswire
  • Montai Health Adds Industry Leaders to its Board of Directors

    Press Release
    May 17, 2023
    Read on Business Wire
  • Flagship Pioneering Unveils Montai Health to Treat and Preempt Chronic Disease Afflicting Two Billion People Worldwide

    Press Release
    December 13, 2022
    Read on The PR Newswire

Join Us

We are growing our team of leaders, committed to finding breakthroughs to make a difference in as many lives as possible.
View Open Positions

Contact Us

  • Partnerships

    We welcome the opportunity to partner with experts across areas who share our passion for creating Anthromolecule medicines and want to collaborate to accelerate the development of safe, efficacious and accessible therapies across diseases.
  • Press

    For media inquiries or the latest on research, thought leadership, company news, and events contact: